David P. Southwell - Feb 2, 2023 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role
Chief Executive Officer, Director
Signature
/s/ David P. Southwell
Stock symbol
TCRX
Transactions as of
Feb 2, 2023
Transactions value $
$0
Form type
4
Date filed
2/6/2023, 04:18 PM
Previous filing
Jan 9, 2023
Next filing
Mar 29, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRX Stock Option (Right to Buy) Award $0 +100K $0.00 100K Feb 2, 2023 Voting Common Stock 100K $1.81 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.